Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Combined With Chemotherapy in PD-1 Inhibitor Resistant Nasopharyngeal Carcinoma
NCT05790200Phase 2Unknown
- Start
- Apr 2023
- Primary completion
- Sep 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in nasopharyngeal carcinoma (NPC). Status: unknown.
02
Drugs
cadonilimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05790200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05790200.